BURLINGAME, Calif.--(BUSINESS WIRE)--Magnus Medical, Inc., a pioneering therapeutic neuromodulation company transforming the treatment of neuropsychiatric disorders, today announced promising new clinical data on SAINT® therapy at the 2024 NYC Neuromodulation Conference, Aug 1-3. The research will be presented in two posters demonstrating the long-lasting benefits of SAINT treatment and its potential for personalized continuation therapy in people with treatment-resistant depression (TRD)..

加利福尼亚州伯灵格姆市——（商业新闻短讯）——Magnus Medical，Inc.，一家开创性的治疗性神经调节公司，致力于神经精神疾病的治疗，今天在2024年8月1日至3日的纽约神经调节会议上宣布了关于SAINT®治疗的有希望的新临床数据。这项研究将在两张海报上展示，展示SAINT治疗的长期益处及其在难治性抑郁症（TRD）患者中进行个性化持续治疗的潜力。。

“We’re excited to share these new findings at this year’s NYC Neuromodulation Conference, which further validate the transformative potential of the SAINT therapy in providing durable relief for people with debilitating intractable depression and offering a pathway for personalized continuation treatment to maintain remission,” said Brandon Bentzley, M.D., Ph.D., co-founder and CSO, Magnus Medical.

Magnus Medical联合创始人兼CSO Brandon Bentzley博士说：“我们很高兴在今年的纽约神经调节会议上分享这些新发现，这进一步验证了SAINT疗法在为衰弱的顽固性抑郁症患者提供持久缓解方面的变革潜力，并为个性化持续治疗提供了一条途径，以维持缓解。”。

“The potential life-saving impact is truly inspiring.”.

“潜在的救生效果确实令人鼓舞。”。

“Furthermore, building on the strength of this compelling research, we are rapidly expanding access to the SAINT neuromodulation system, delivering it to hospitals and private clinics across the country,” continued Dr. Bentzley.

“此外，在这项引人注目的研究的基础上，我们正在迅速扩大圣神经调节系统的使用范围，将其提供给全国各地的医院和私人诊所，”本兹利博士继续说道。

Research Highlights:

研究亮点：

Durability of clinical benefit with Stanford Neuromodulation Therapy (SNT, commercially known as SAINT) in treatment-resistant depression: assessment of sustained remission and response following index treatment

斯坦福神经调节疗法（SNT，商业上称为SAINT）治疗难治性抑郁症的临床益处的持久性：指数治疗后持续缓解和反应的评估

This study, conducted by researchers at Stanford University, provides the first longer-term data on the durability of SAINT's antidepressant effect in patients with TRD. The results indicate that a single five-day course of treatment offers substantial and durable clinical benefits, with patients remaining in remission for an average of 11 weeks and in a state of response for an average of 15 weeks..

这项由斯坦福大学（StanfordUniversity）研究人员进行的研究首次提供了关于圣人抗抑郁药对TRD患者的持久性的长期数据。。。

An Open-Label Pilot Trial to Assess the Feasibility of Using the Magnus Neuromodulation System with Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) as a Personalized Continuation Therapy for Depression

一项开放标签的试点试验，旨在评估使用Magnus神经调节系统和斯坦福加速智能神经调节疗法（SAINT）作为抑郁症的个性化延续疗法的可行性

This study, led by Magnus Medical with Acacia Clinics, investigated the use of SAINT as a personalized continuation therapy for people with TRD who initially responded to an acute course of SAINT treatment. The results demonstrate that this approach is safe, well-tolerated, and highly effective in maintaining remission from depression for 12 months..

这项由Magnus Medical和Acacia诊所领导的研究调查了SAINT作为TRD患者的个性化延续疗法的使用，这些患者最初对SAINT的急性疗程有反应。结果表明，这种方法是安全的，耐受性良好，并且在维持抑郁症缓解12个月方面非常有效。。

Treatment with SAINT changes a person’s brain circuitry to treat major depression more effectively by modifying activity in brain networks that are related to depression. Granted Breakthrough Device Designation and 510(k) clearance by the U.S. Food & Drug Administration (FDA), SAINT therapy has led to dramatic improvements in people’s symptoms of severe depression in a clinical setting..

SAINT治疗改变了一个人的大脑回路，通过改变与抑郁症相关的大脑网络的活动，可以更有效地治疗重度抑郁症。SAINT therapy获得了美国食品和药物管理局（FDA）的突破性设备指定和510（k）许可，在临床环境中，人们的严重抑郁症症状得到了显着改善。。

SAINT therapy works by leveraging structural and functional magnetic resonance imaging (MRI) scans to inform a proprietary algorithm that pinpoints the optimal anatomical target for precise neurostimulation in individuals with major depression. The innovative treatment is performed on an accelerated, five-day timeline, ensuring that stimulation targeting is meticulously customized to each person’s unique brain connectivity..

SAINT therapy的工作原理是利用结构和功能磁共振成像（MRI）扫描来通知专有算法，该算法可以精确定位抑郁症患者精确神经刺激的最佳解剖目标。这种创新治疗是在一个加速的五天时间表上进行的，确保刺激目标是根据每个人独特的大脑连接精心定制的。。

About Magnus

关于马格纳斯

Magnus Medical, Inc., is a privately held therapeutic neuromodulation company driven to transform lives by restoring mental health. Co-founded in 2020, the company’s first product is the SAINT neuromodulation system, which provides a new form of individualized neurostimulation for treatment-resistant depression indicated for adults who have failed to achieve satisfactory improvement from prior antidepressant medications.

Magnus Medical，Inc.是一家私营的神经调节治疗公司，旨在通过恢复心理健康来改变生活。该公司于2020年共同成立，其首款产品是SAINT神经调节系统，该系统为治疗难治性抑郁症提供了一种新形式的个性化神经刺激，适用于那些未能从先前的抗抑郁药物中获得令人满意改善的成年人。

For more information, visit https://www.magnusmed.com..

For more information, visit https://www.magnusmed.com..